NCT04150744View on ClinicalTrials.gov

RFA Plus Carrizumab vs Carrizumab Alone for HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Tumor ImmunityImmunosuppressionRadiofrequency Ablation
Interventions
COMBINATION_PRODUCT

radiofrequency ablation

take advantage of RFA to destroy hepatocellular carcinoma by high temperature

Trial Locations (1)

310000

RECRUITING

the Second Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER